Titan Pharmaceuticals (NASDAQ:TTNP) & Exelixis (NASDAQ:EXEL) Financial Survey

Titan Pharmaceuticals (NASDAQ:TTNP) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Profitability

This table compares Titan Pharmaceuticals and Exelixis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Titan Pharmaceuticals	N/A	-118.01%	-103.79%
Exelixis	24.04%	23.52%	17.95%

Insider & Institutional Ownership

31.5% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 24.9% of Titan Pharmaceuticals shares are owned by company insiders. Comparatively, 2.9% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Titan Pharmaceuticals and Exelixis, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Pharmaceuticals	0	0	0	0	0.00
Exelixis	2	6	12	0	2.50

Exelixis has a consensus target price of $37.59, suggesting a potential upside of 3.86%. Given Exelixis’ stronger consensus rating and higher possible upside, analysts plainly believe Exelixis is more favorable than Titan Pharmaceuticals.

Volatility & Risk

Titan Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Earnings and Valuation

This table compares Titan Pharmaceuticals and Exelixis”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Pharmaceuticals	$180,000.00	18.46	-$5.57 million	($5.21)	-0.70
Exelixis	$2.17 billion	4.67	$521.27 million	$1.77	20.45

Exelixis has higher revenue and earnings than Titan Pharmaceuticals. Titan Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Summary

Exelixis beats Titan Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.